Immunome initiates coverage with hold rating; price target $24
IMNM•Stifel initiated coverage of Immunome with a hold rating and a $24 price target.
Related News
Freshpet, Inc.: Needham initiates coverage with hold rating
FRPT•
Wave Life Sciences plans single two-year WVE-006 trial after FDA feedback
WVE•
Unicycive Therapeutics appoints Meredith Manning to board, names her nominating committee chair
UNCY•
E-Home Household Service launches project to develop AI service robot
EJH•
NextEra Energy CEO John Ketchum joins Wolfe Research conference fireside chat
NEE•